PET/CT Scans | NYU Langone Health
NYU Langone offers PET/CT scans to diagnose illness, evaluate treatments, and assess the recurrence of many conditions, including cancer.
Phase 1 First-In-Human Study to Explore the Safety Tolerability and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
The tumor-associated antigens mesothelin (MSLN) and cadherin-3 (CDH3) areco-expressed in multiple tumor types, with minimal overlap observed in normal tissues.AMG 305 is a first dual-targeting BiTE (dBiTE™) molecule (CDH3-MSLN half-life extended [HLE] dBiTE™ AND dual targeting, HLE BiTE molecule) that targets the antigens P-cadherin (CDH3) and MSLN as well as CD3 on T-cells. AMG 305 is designed to increase the therapeutic index in solid tumors by preferentially targeting tumor cells that co-express CDH3 and MSLN over normal cells that express only 1 of these targets.
Phase 1 study of intratumoral administration of JNJ-87704916 an oncolytic virus as monotherapy and in combination for advanced solid tumors
This is a phase 1 study, testing the study medicine JNJ-87704916 (an oncolytic herpes simplex virus type 1, HSV-1) alone or in combination with another medicine, cetrelimab (a PD-1 antibody), in patients with advanced solid tumors. This study has two parts. In part 1 of the study, the study team will gradually increase the dose of the study medicine to find out the most effective dose that works well with fewer side effects. In part two, the patients will be divided into two groups. Group A will include patients whose lung cancer has spread from the primary location and the tumor has no PDL-1 expression (PD-L1
Phase 1/2 Multi-Center Open-Label Study to Evaluate the Safety Tolerability and Preliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, andPreliminary Anti-tumor Activity of TNG462 in Patients with MTAP-deleted Advanced or Metastatic Solid Tumors
Phase 1/2 Study of PARG Inhibitor ETX-19477 in Patients with Advanced Solid Malignancies
This study is designed to test how the drug moves through the body (pharmacokinetics), how it works (pharmacodynamics), and how well it fights tumors. The drug being tested is ETX-19477, which targets a specific protein in cancer cells. The study has two parts: Phase 1 will test different doses of the drug to find the dose with the least amount of side effects that works, and Phase 2 will look at how well that dose works for treating cancer. In Phase 1, patients will be given different amounts of the drug to see which dose is best tolerated, starting with small doses and increasing them if it’s safe. Researchers will keep track of patients’ health and any side effects, and check how well the drug helps shrink the tumors. The goal is to find the best dose and learn how well ETX-19477 works against advanced cancers.
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with estrogen receptor-positive (ER+) human epidermal growth factor receptor 2 (HER2)-negative locally advanced and unresectable or metastatic breast cancer expressing somatostatin receptors (SSTRs) and progressed after antibody-drugconjugates and/or chemotherapy (TRACY-1)
This is a phase 1b/2 study testing whether the study medicine RYZ101 (targeted radiopharmaceutical therapy) will be a safe and better option for treating patients with ER+, HER2-negative breast cancer. This study will be done in two parts. In the first part, patients will be sequentially enrolled and divided into groups to receive study medicine at different dose levels. The study team will find out the dose that works well and has fewer side effects. In the second part of the study, more patients will be included to receive the study medicine that was effective and had fewer side effects for patients in the first part. All patients will have blood samples taken to see how their bodies are handling the study medicine. Special scans will be taken for all patients to see how the study medicine is changing their cancer. The study team will monitor all patients for side effects and safety.
Phase 2/3 Multistage Multicenter Randomized Double-Blind Placebo-Controlled Parallel Group Withdrawal Study to Evaluate the Efficacy and Safety of Nipocalimab Administered to Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
The purpose of this study is to see if nipocalimab is safe and useful for treating participants with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). This is the first study where nipocalimab is being administered to participants with CIDP.
Phase 3 multicenter randomized double-blind group sequential placebo-controlled study to assess efficacy and safety of rimegepant for the treatment of migraine (with or without aura) in children and adolescents = 6 to
The main purpose of this study is to learn how well the study drug works and how safe the study drug is in children and young people compared with placebo. A placebo is an inactive material that looks like the study drug but does not contain any active study drug. Researchers use a placebo to see if the study drug works better or is safer than taking nothing.
Phase 3 Randomized Open-label Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan in Combination with Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants with Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
This is a Phase 3 trial testing whether the study medicine sacituzumab tirumotecan (an antibody-drug conjugate, also known as sac-TMT, or MK-2870), when given in combination with another medicine called pembrolizumab (an immunotherapy medicine), is effective and a better treatment in patients with a specific type of endometrial cancer called proficient (pMMR) endometrial cancer. This trial will compare treatment with sac-TMT plus pembrolizumab to pembrolizumab alone. This study has two parts- Part 1 is the Induction phase, where patients will receive pembrolizumab and chemotherapy, and Part 2 is the Maintenance phase, where patients whose cancer has not progressed, as shown by the CT scans, will be divided into two groups to receive either sac-TMT plus pembrolizumab or pembrolizumab alone. Patients will undergo CT scans during the study to see how their cancer is changing in response to the study treatment. Blood samples will be taken from all patients to see how their bodies are handling the study medicine. All patients will be closely monitored for any side effects and safety concerns.
Phase I open-label trial evaluating BI 1810631 as monotherapy in the treatment of patients with advanced or metastatic solid tumors with HER2 aberrations (BEAMION-Lung 1)
This is a Phase I, open-label, multicentre trial of BI 1810631 administered orally as a singleagent. The trial has two parts; Phase Ia, which is the dose escalation part (non-randomised),and Phase Ib which is the dose expansion part. The dose expansion part will consist of 3cohorts. If needed, the expansion part will include a randomised dose optimization in Cohort1